Background. Hereditary renal hypouricemia may be complicated by nephrolithiasis or exercise-induced acute renal failure. Most patients described so far are of Japanese origin and carry the truncating mutation W258X in the uric acid transporter URAT1 encoded by SLC22A12. Recently, we described severe renal hypouricemia in Israeli patients with uric acid transporter GLUT9 (SLC2A9) lossof-function mutations. Renal hypouricemia in Iraqi Jews has been previously reported, but its molecular basis has not been ascertained. Methods. Three Jewish Israeli families of Iraqi origin with hereditary hypouricemia and hyperuricosuria were clinically characterized. DNA was extracted and the URAT1 gene was sequenced. Transport studies into Xenopus laevis oocytes were utilized to evaluate the function of URAT1 mutants found. Results. A missense URAT1 mutation, R406C, was detected in all three families. Two affected siblings were found to carry in addition a homozygous missense URAT1 mutation, G444R. Both mutations dramatically impaired urate uptake into X. laevis oocytes. Moreover, we demonstrate for the first time that URAT1 facilitates urate efflux, which was abolished in the mutants, indicating also a secretion defect. Homozygous patients had serum uric acid concentrations of 0.5-0.8 mg% and a fractional excretion of uric acid of 50-85%. Most individuals studied were asymptomatic, two had nephrolithiasis and none developed exercise-induced acute renal failure. Conclusions. The URAT1 R406C mutation detected in all three families is likely to be the founder mutation in Iraqi Jews. Our findings contribute to a better definition of the different types of hereditary renal hypouricemia and suggest that the phenotype of this disorder depends mainly on the degree of inhibition of uric acid transport.
Introduction
Uric acid (UA) is the end product of purine metabolism in humans. Elevation of serum UA levels has been associated with various diseases, including gout, hypertension, cardio-URAT1 mutations cause renal hypouricaemia type 1 in Iraqi Jews 2175 vascular and renal diseases. Conversely, UA has a beneficial role as a natural antioxidant, and low serum UA levels have also been linked to several neurologic diseases [1, 2] . The current model of urinary UA excretion consists of four components: a free glomerular filtration, a near complete re-absorption of the filtered UA and a secretion followed by post-secretion re-absorption [3, 4] . The location and molecular physiology of the three tubular transport components, however, have not been completely clarified. Genetic analysis of Japanese patients with renal hereditary hypouricemia (RHUC) revealed homozygous or compound heterozygous loss-of-function mutations of URAT1, a renal UA/anion exchanger [3, 5] ; most of them carried at least one allele with the truncation mutation W258X [5] [6] [7] . These patients were characterized by low levels of serum UA, high fractional excretion of UA (FE UA ) and a diminished alteration of UA excretion upon pyrazinamide and probenecid application [6] . Most of these patients were asymptomatic, but some had nephrolithiasis or were predisposed to develop exercise-induced acute renal failure (EIARF). Although URAT1 mutations seem to be a rare event outside Japan [8, 9] , clinical features of several cases of familial hypouricemia and hyperuricosuria in Iraqi Jews have been reported [10, 11] . However, the molecular basis of hypouricemia in these cases has not been elucidated.
GLUT9, a member of the facilitated glucose transporters, encoded by SLC2A9, was recently associated with serum UA levels and gout in several population studies [12] [13] [14] and was also shown to be a potent UA transporter in vitro [12, 15] . In a previous study, we have shown that homozygous loss-of-function mutations of SLC2A9 cause severe renal hypouricemia complicated by nephrolithiasis and EIARF [16] .
In this report, we reveal the molecular basis of RHUC in Iraqi Jews and clarify the similarities and differences between RHUC caused by URAT1 and GLUT9.
Materials and methods

Clinical analysis
Index patients and family members were evaluated for clinical history of renal stones, exercise-induced acute renal injury or other renal diseases. Blood and spot urine samples were collected for measurement of UA and creatinine levels and for genetic analysis. The study was approved by the institutional and Ministry of Health review boards for human experimentation. All participants gave written informed consent. Parental consent was obtained for a 17-year-old subject.
Molecular analysis DNA extraction and sequencing. Genomic DNA was isolated from peripheral blood cells applying the ArchivePure DNA Blood Kit (5 PRIME, Gaithersburg, MD, USA) according to the manufacturer's instructions. Intronic primers were designed to amplify the coding areas and splice sites of SLC22A12 by PCR (see the Supplemental Appendix for primer sequences). All PCR products were sequenced directly (ABI Prism 3100; Applied Biosystems, Foster City, CA, USA).
Restriction enzyme analysis. Restriction enzyme analysis was used to confirm the sequence results and to screen normal controls. Exon 7 and exon 8 of SLC22A12 were amplified using flanking intronic primers and digested with the restriction enzymes MspA1I and AciI, respectively. The digested fragments were detected using gel electrophoresis.
Molecular/functional studies Plasmids. pBS-MXT-URAT1 was generated by inserting an URAT1 cDNA fragment flanked by HindIII (5′) and EcoRI (3′) sites into the corresponding sites of pBS-MXT. Additionally, we used hURAT1-pcDNA3.1 plasmid (kindly provided by Prof. Dr H. Endou, Kyorin University, Tokyo, Japan) as a control.
Transport studies. Xenopus laevis oocytes (Nasco, Fort Atkinson, WI, USA) were prepared, injected and cultivated as previously described [17] 
Results
Clinical characteristics Family 1. The index patient (F1I1) was a 68-year-old man with type 2 diabetes mellitus, hypertension and ischemic heart disease for which he underwent a coronary arterial bypass surgery. A low serum UA level (0.8 mg%) was noted in repeated routine examinations and urinary UA excretion was found to be elevated (FE UA : 85%). He had no episodes of renal colic or acute kidney injury. His parents are not known to be closely related, but are both of Iraqi Jewish origin. His 35-yearold healthy daughter (F1I2) had a serum UA of 1.7 mg% (Table 1) .
Family 2. The index patient (F2I1) was a 35-year-old Iraqi-Jewish woman who developed hypertension during her second pregnancy. Primary hyperaldosteronism with adrenal hyperplasia was diagnosed, and at the same time hypouricemia (serum UA: 0.5 mg%) and hyperuricosuria (FE UA : 72%) were noted. The patient had no history of renal colic or acute kidney injury. Her older brother who had been previously diagnosed with nephrolithiasis was also found to have renal hypouricemia (F2I2).
Family 3. The index patient (F3I4) was a 62-year-old Iraqi-Jewish man with end-stage renal failure of unknown cause. A kidney biopsy showed glomerular sclerosis and tubular atrophy. A successful pre-emptive living related kidney transplant was performed. After transplantation, he was noted to have a low serum UA (1.5 mg%) with a serum creatinine of 1.5 mg%. His younger sister who donated the kidney (F3I6) had a serum UA of 0.8 mg% and a FE UA of 82%. An older brother with chronic kidney disease after heart transplantation (F3I3) had a serum UA of 4.1 mg%. Other family members had serum UA levels of 2.2-3.4 mg%. None of them had a history of EIARF, but one had a kidney stone (F3II3).
Clinical features and data related to UA handling of all studied individuals are shown in Table 1 .
Molecular analysis
We found in all three families a novel missense mutation of SLC22A12, c.1216C >T, which changes arginine 406 to cysteine in URAT1 (R406C; Figure 1A -1, Table 1 ). The index patient of family 1 (F1I1) was homozygous and his daughter (F1I2) was a heterozygous carrier of this mutation. The index patient of family 3 (F3I4) was heterozygous for the R406C mutation, but his kidney donor (F2I6) was found to be homozygous. The two siblings with renal hypouricemia in family 2 (F2I1; F2I2) carry a heterozygous R406C mutation. However, in both of them, we also found a second novel homozygous missense mutation, c.1330G>A, which changes glycine 444 to arginine (G444R; Figure 1A -2, Table 1 ).
Sequence results were confirmed by restriction enzyme analysis of all available family members ( Figure 1B ). Both mutations, R406C and G444R, were absent in control group of 100 unrelated normal Israeli subjects (200 alleles), including 18 unrelated individuals of Iraqi origin. Amino acids R406 and G444 are located in transmembrane domains 10 and 11, respectively ( Figure 1D ). Amino acid R406, but not G444, was found to be conserved in URAT1 of other species ( Figure 1C-1) as well as in human OAT4 and OAT1 ( Figure 1C-2) .
Functional studies
In order to determine the effect of the mutations of URAT1 found in our patients, we measured [
14 C]urate uptake in X. laevis oocytes injected with URAT1 wild-type (URAT1-wt) or the mutants URAT1-R406C and URAT1-G444R. URAT1-wt showed substantial uptake of [ 14 C]urate (set to 100%, Figure 2A ), which could be inhibited by probenecid (31.2%). However, URAT1-R406C and URAT1-G444R exhibited significantly reduced urate transport with 36.6 and 37.3% of URAT1-wt uptake, respectively. Interestingly, the mutants behaved differently in terms of probenecid inhibition. Whereas mutant URAT1-G444R showed no difference in urate transport in the presence of probenecid (38.2%), URAT1-R406C demonstrated a significant uptake of urate upon adding 1 mM of probenecid (72.7%), indicating substance-specific effects on the two mutants. Due to the fact that hypouricemia might also be a result of a change in renal urate secretion, we tested the efflux of [ ]urate could not be trans-stimulated by 1 mM lactate in the external medium in mock oocytes, URAT1-wt and URAT1-R406C. However, a small but significant trans-stimulation of urate efflux was determined for the URAT1-G444R mutant, suggesting a different effect of the mutant on urate transport.
Discussion
Some of the first clinical reports of hereditary RHUC described patients of Iraqi-Jewish origin. These patients had a serum UA of 0.6-1.0 mg% with no other renal tubular defects, and their response to pyrazinamide-probenecid test was interpreted as compatible with a pre-secretory absorption defect [10, 11] .
Here, we show that RHUC in Iraqi Jews is caused by missense mutations of URAT1. We studied three unrelated Israeli families of Iraqi-Jewish origin with hereditary hypouricemia and found in all three families a novel missense URAT1 mutation, R406C. It is likely that the R406C mutation is the common URAT1 defect in the Iraqi-Jewish population. In Family 2, we detected a second novel homozygous missense mutation, G444R. Both mutations affect amino acids in or close to the substrate binding region [18] and are absent in control individuals, including Iraqi-Jewish controls. Functional studies in oocyts revealed that both R406C and G444R mutations markedly reduced UA transport (Figure 2) confirming the loss-of-function nature of these mutations. Considering that mutation R406C hits the loop region between transmembrane domain (TMD) 8, which is crucial for substrate binding, and TMD9, we observed that this mutant behaves differently in the presence of 1 mM probenecid. Some authors postulate two possible substrate binding sites for the SLC22A family of organic anion and cation transporters (OATs and OCTs), of which URAT1 is a member [18, 19] . Consequently, we speculate that instead of inhibiting URAT1-mediated UA transport, probenecid may modify the binding pocket towards a higher affinity for UA and therefore partly reverse the effect of the mutation. Hypouricema has so far been as a loss-of-function mutation in the URAT1 gene resulting in a reduced re-absorption of UA. Due to the fact that the exact mechanism of UA secretion is not yet clear, one might speculate that URAT1 could also be involved in UA secretion to the tubular lumen. To prove this concept, we tested the efflux of UA via URAT1. We demonstrate for the first time that URAT1 is capable of facilitating UA efflux. Both mutants did not show any UA efflux and for URAT1-G444R we even observed a lower UA efflux as the mock oocytes, which might be explained by the different behavior of both mutants. Interestingly, UA efflux via URAT1 was not elevated in the presence of 1 mM lactate in the external medium, which is one of the main driving forces for urate uptake [5] , suggesting an asymmetric interaction of URAT1 with lactate. We cannot exclude that lactate was taken up by the oocytes and re-used as a substrate leading to the lack of lactate effect during UA efflux. It was shown by others that URAT1 is not pH dependent like organic anion transporter 4 [5, 20] . However, OAT4 as well as URAT1 show Cl − dependence resulting in terms of OAT4 into the most elegant physiological mechanism of organic anion (OA) and therefore p-aminohippurate/drug excretion via Cl − /OA exchange [20] . UA uptake by URAT1 was demonstrated to be elevated by removal of extracellular chloride, indicating urate/Cl − exchange [5] . This mode of action will never take place under physiological conditions due to the missing inside/out Cl − gradient. But we speculate that the driving force for UA secretion via URAT1 might be Cl − similar to the transport mechanism of OAT4 [20] . The loss of UA efflux function of the URAT1 mutants may result in a different total re-absorption of UA, according to the four-component model of renal UA handling [4] . A total of 23 ng of cRNA encoding hURAT1-wt or the mutants hURAT1-R406C or hURAT1-G444R were injected into each oocyte, and the same volume of water was injected for the mock oocytes. After 3 days of incubation, uptake experiments were performed with 100 μM [ 14 C]urate for 30 min in the presence or absence of 1 mM probenecid. Data are means ± SEM of three independent experiments with 8-11 oocytes each. The uptakes were standardized by setting the uptake of hURAT1-wt-expressing oocytes without probenecid to 100% and subtracting mock values for all measured values (equivalent to % over control).The difference in urate uptake between WT and R406C or G444R in ORI is highly significant (P < 0.001). *P < 0.05. ORI: oocyte ringer. (B) Urate efflux studies on Xenopus laevis oocytes that were injected with water (mock), hURAT1-wt-, hURAT1-R406C-or hURAT1-G444R-cRNA. Three days after cRNA or water injection, 46 nL of [ C content recovered in the supernatant compared with the sum of total radioactivity recovered in the medium and that remaining in the oocytes at the conclusion of a 30-min efflux period at room temperature. Data are means ± SEM of two to three independent experiments with six oocytes each. The difference in urate efflux using ORI between WT and R406C or G444R is highly significant (P < 0.001). **P< 0.01, ***P< 0.001. Subjects with homozygous R406C or G444R mutations had a serum UA concentration of 0.5-1.0 mg% and a FE UA of 50-85%, while heterozygous subjects with normal kidney function had a serum UA of 1.7-3.4 mg% and a FE UA of 11-16%. Interestingly, the heterozygous index patient of Family 3 (F3I4), who received a kidney transplant from his homozygous sister (F3I6), had a serum UA of 1.5 mg% and a FE UA of 38% in spite of calcineurin inhibitor treatment and an elevated serum creatinine ( Table 1) .
The values of serum UA and UA renal excretion of our Iraqi-Jewish patients are very similar to those of Japanese patients with the W258X URAT1 mutation [7] . In contrast, patients with renal hypouricemia due to homozygous GLUT9 mutations have much lower serum UA levels and a FE UA of > 150%, compatible with a total UA reabsorption defect [16] . These findings enable us to define the clinical characteristics of renal hereditary hypouricemia caused by URAT1 mutations (RHUC1, OMIM #220150), as opposed to renal hereditary hypouricemia caused by GLUT9 mutations (RHUC2, OMIM #612076) ( Table 2 ). Since we can now confirm the diagnosis of RHUC types 1 or 2 using molecular analysis, the pyrazinamide/probenecid test is no longer required.
Both RHUC1 and RHUC2 may be complicated by nephrolithiasis and EIARF [7, 16, 21] . The mechanism of EIARF in patients with renal hypouricemia has not been clarified. Two explanations have been previously proposed: (i) acute urate nephropathy due to increased production of UA during physical exercise and (ii) ischemic kidney injury secondary to exercise-induced oxidative stress, in the absence of the protective effect of UA, a powerful serum antioxidant [3] . Although serum UA levels and UA fractional excretion in our Iraqi-Jewish patients were similar to those of Japanese patients with the W285X mutation and EIARF [7] , none of our patients experienced EIARF. This cannot be attributed to unique environment or genetic background of Japanese patients since, as we have shown before, Israeli patients with hereditary renal hypouricemia due to GLUT9 mutations are at risk of EIARF [16] .
We have proposed a third mechanism for EIARF [16] : URAT1 is a urate/anion exchanger [5] . Therefore, inactivation of URAT1 by loss-of-function mutations of either URAT1 or GLUT9 will not only abolish UA absorption but will also block secretion of organic anions to the tubular lumen. We speculate that tubular accumulation of toxic urate-coupled organic anions produced during exercise (such as lactate) may exert toxic effects on renal proximal tubules, leading to toxic acute tubular injury. Whether the truncating W258X mutation has a greater impact on anion excretion than the Iraqi R406C missense mutation is yet to be proved.
In conclusion, we provide evidence for the genetic background of RHUC in Iraqi Jews, the second population proven to suffer from RHUC type 1. Both mutations we detected, namely R406C and G444R, exhibited reduced urate uptake. Our findings contribute to a better definition of RHUC types 1 and 2 and suggest that the phenotype of this disorder depends mainly on the degree of inhibition of uric acid transport.
SUPPLEMENTARY APPENDIX -SLC22A12 Primers' sequences
Primer name Primer sequence (5' → 3') URAT1X1F TGG CCT CTT TGC CCT GGG CC URAT1X1R ACC CAC CGT GAT CCA TGA CTG ACC TCT C URAT1X2F CTG CCT CTC TGC TGG GGC TC URAT1X2R TCG GCC AGG GTC CTA GGA GAG URAT1X3F TCC AGA GCC CCG TGG CCT GTG URAT1X4R CGG GTG GAG AGT GGG CAG GAT C URAT1X5F AGG CTG GCG CAG GCC AGG C URAT1X6R GTG TGC CAG CGA GAG CCC CG URAT1X7F CCT GAG CCC CCA CCG CCC ATT GTT URAT1X7R CCT GCT CTA GTC CAG CAC CTC CAA URAT1X8F AGG GAG CCC TCA TCT GAT CTT GGG C URAT1X9R TGC CCT GTG CTA GGG TTC TCT GGT G URAT1X10F CAG GTC AAG GGT CAG GGG CCA CTC URAT1X10R CCT GCC TTC TCC CAG AGA ACA GAA GAA GTC Conflict of interest statement. None declared.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder with an incidence of 1:1000 individuals [1] . ADPKD is characterized by abnormal proliferation of renal tubular epithelial cells, which manifests as renal cysts that grow in both size and number leading to massive kidney enlargement and progressive decline in renal function [2] . ADPKD is one of the most common causes of end-stage renal disease (ESRD), accounting for~5% of all individuals requiring dialysis or kidney transplantation [1] . Extrarenal cystic manifestations are common, of which hepatic cysts are the most clinically relevant. The most important non-cystic disease association are intracranial aneurysms that occur in~8% of patients with ADPKD with evidence of familial clustering [3] . So far, there are no effective treatments for patients with ADPKD. Gattone et al. were able to show in an animal model that vasopressin V2 receptor (VPV2R) inhibited disease development and either halted progression or caused regression of established disease [4] . Additionally, Hogan et al. could show in a clinical trial that octreotide, a long-acting somato-
